Apex Meds Get started
All peptides

BPC-157 · Recovery & repair One peptide.
One job.
Support the repair.

BPC-157 prescribed on its own, for people who want a single, readable starting point. Evaluated by a licensed Apex Meds provider and filled by a licensed U.S. pharmacy.

$249per month · injectable
Apex Meds BPC-157 vial
Form
Subcutaneous injection
Course
A set cycle, then a break
Prescribed by
Licensed Apex Meds provider
Length
15 amino acids
What is BPC-157?

BPC-157, in plain terms

BPC stands for Body Protection Compound. BPC-157 is a synthetic peptide of 15 amino acids, modelled on a fragment of a protective protein first described in human gastric juice in 1993.

It is not a component of any approved drug. It is prescribed as a compounded medication after a provider reviews your history.

What the research shows
What it has been studied for

The findings, and the kind of study behind each

Tendon, muscle, ligament

A 2025 review found 35 animal and lab studies showing improved healing of muscle, tendon, ligament and bone.

Animal and lab

Blood flow

In rats with restricted circulation to a limb, BPC-157 improved the recovery of blood flow.

Animal and lab

Tendon cells

Tendon cells exposed to BPC-157 grew out, survived stress and migrated faster.

Animal and lab

Human data

Limited to a few small, uncontrolled pilot studies, including one in knee pain.

Early human
Who asks about it

People who want to move better, for longer

Coming back from injury

People returning from a tendon, muscle or ligament setback, alongside their rehab.

Active lifestyles

People who train most days and want a physician-guided recovery plan.

A recurring sore spot

People with an ache that keeps returning, who have already had it checked.

A simple starting point

People who want one peptide, so their response is easy to read.

These describe the people who ask about BPC-157, not results. A licensed provider decides whether it is appropriate for you.

How it works

What it does in the body

In laboratory work, BPC-157 increased the activity of a receptor on blood-vessel cells (VEGFR2) that drives nitric oxide production and new capillary growth. In tendon cells it switched on a pathway that governs how cells spread and migrate.

These findings come from cell and animal studies. The FDA's own review notes that the peptide's exact molecular target has not been identified.

Blood vessels

A receptor that drives new capillary growth

Tendon cells

A pathway that governs how cells spread and migrate

Still being mapped

Its exact molecular target has not been identified

What to expect

On the protocol

01

How it's taken

A small injection just under the skin over a set cycle, followed by a break. Your provider sets the dose, the schedule and the length of the cycle. It arrives already reconstituted by the pharmacy, so there is no powder to mix and nothing to measure out.

02

What people report

Patients commonly describe first changes in pain or mobility within a few weeks. These are patient reports, not trial outcomes, and results are not guaranteed.

03

Keep your care team

Peptides are not a substitute for diagnosis, physical therapy or orthopaedic care. Tell your provider about any injury you are treating.

Why Apex Meds

A higher standard in peptide therapy

  • Reviewed by a licensed provider
  • Filled by a licensed U.S. pharmacy
  • Arrives reconstituted, ready to use
  • Made for human use, never “research only”
  • Medical support while you are on it
Start my evaluation
Frequently asked questions

BPC-157 questions, answered

Is BPC-157 FDA-approved?

No. It is not approved for any condition. When prescribed it is a compounded medication, which has not been reviewed by the FDA for safety, effectiveness or quality.

Is there human research?

Very little. A few small, uncontrolled pilot studies exist. Most of the evidence comes from animal and cell studies.

How is it taken?

Typically as a small subcutaneous injection over several weeks, under your provider's direction.

How soon will I notice anything?

Patients commonly describe a few weeks, but that comes from patient reports rather than controlled trials. Results are not guaranteed.

What are the risks?

Injection-site reactions are the most common. Long-term safety has not been studied. People with cancer, or who are pregnant, should not use it.

Can I use it if I compete in tested sports?

No. BPC-157 is prohibited at all times under the World Anti-Doping Agency's rules for non-approved substances. It is also prohibited by the NCAA and the U.S. Department of Defense.

What should I know before I start?

Your provider reviews your full history, so tell them about every medication and condition, including any history of cancer. Reported side effects: redness or swelling at the injection site; mild nausea; headache or fatigue; long-term safety has not been studied. Who should not use it: active cancer or a recent history of cancer; pregnancy or breastfeeding; anyone under 18; athletes subject to drug testing.

Keep looking

Other peptides from Apex Meds

Physician-prescribed peptide therapy

Start with BPC-157

Answer a few questions. A licensed Apex Meds provider decides whether it is right for you.

  • Expert guidance
  • Personalised care
  • Ongoing support

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Prescription products require an online evaluation with a licensed medical professional, who will determine whether a prescription is appropriate. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality. Research cited on this site describes published studies and is not a claim about what any product will do for you. Individual results vary.

Sources
  1. Vasireddi et al., systematic review, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
  2. Chang et al., J Appl Physiol, 2011. https://pubmed.ncbi.nlm.nih.gov/21030672/
  3. Hsieh et al., J Mol Med, 2017. https://link.springer.com/article/10.1007/s00109-016-1488-y
  4. Lee & Padgett, 2021. https://pubmed.ncbi.nlm.nih.gov/34324435/
  5. FDA evaluation of BPC-157, 2026. https://www.fda.gov/media/193343/download